

NEUROLOGY AND
NEUROBIOLOGY
VOLUME 8B



CATECHOLAMINES
Part B:
Neuropharmacology and
Central Nervous System-
Theoretical Aspects

Editors
Earl Usdin
Arvid Carlsson
Annica Dahlström
Jörgen Engel

Alan R. Liss, Inc., New York

CATECHOLAMINES

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

**Proceedings of the Fifth International Catecholamine
Symposium, held in Göteborg, Sweden, June 12–16, 1983**

Editors

Earl Usdin

Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine
Irvine, California

Arvid Carlsson

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

Annica Dahlström

Institute of Neurobiology
University of Göteborg
Göteborg, Sweden

Jörgen Engel

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

ALAN R. LISS, INC., NEW YORK

Address all Inquiries to the Publisher
Alan R. Liss, Inc., 150 Fifth Avenue, New York, NY 10011

Copyright © 1984 Alan R. Liss, Inc.

Printed in the United States of America.

Under the conditions stated below the owner of copyright for this book hereby grants permission to users to make photocopy reproductions of any part or all of its contents for personal or internal organizational use, or for personal or internal use of specific clients. This consent is given on the condition that the copier pay the stated per-copy fee through the Copyright Clearance Center, Incorporated, 21 Congress Street, Salem, MA 01970, as listed in the most current issue of "Permissions to Photocopy" (Publisher's Fee List, distributed by CCC, Inc.), for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Library of Congress Cataloging in Publication Data

International Catecholamine Symposium (5th : 1983 :
Göteborg, Sweden)

Catecholamines : proceedings of the Fifth International
Catecholamine Symposium, Held in Göteborg, Sweden,
June 12-16, 1983.

Includes bibliographies and indexes.

Contents: pt. A. Basic and peripheral mechanisms--
pt. B. Neuropharmacology and central nervous system--
theoretical aspects--pt. C. Neuropharmacology and central
nervous system--therapeutic aspects.

1. Catecholamines--Congresses. 2. Adrenergic
mechanisms--Congresses. 3. Catecholamines--Therapeutic
use--Congresses. 4. Neuropharmacology--Congresses.

I. Usdin, Earl. II. Title. [DNLM: 1. Catecholamines--
Congresses. WI NE337B v.8 / WK 725 I59 1983c]

QP801.C3315 1983 615'.78 84-3967

Part A: ISBN 0-8451-2707-1

Part B: ISBN 0-8451-2708-X

Part C: ISBN 0-8451-2709-8

Three-Volume Set: ISBN 0-8451-2798-5

CATECHOLAMINES

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

Neurology and Neurobiology

EDITORS: Victoria Chan-Palay and Sanford L. Palay

The Harvard Medical School

ADVISORY BOARD

Günter Baumgartner

University Hospital, Zurich

Bruce McEwen

Rockefeller University

Gösta Jonsson

Karolinska University

Masao Ito

Tokyo University

William D. Willis, Jr.

The University of Texas, Galveston

Volume 1

Cytochemical Methods in Neuroanatomy

Victoria Chan-Palay and Sanford L. Palay, *Editors*

Volume 2

Basic Mechanisms of Neuronal Hyperexcitability

Herbert H. Jasper and Nico M. van Gelder, *Editors*

Volume 3

Anorexia Nervosa: Recent Developments in Research

Padraig L. Darby, Paul E. Garfinkel, David M. Garner, and Donald V. Coscina, *Editors*

Volume 4

Clinical and Biological Aspects of Peripheral Nerve Diseases

Leontino Battistin, George A. Hashim, and Abel Lajtha, *Editors*

Volume 5

The Physiology of Excitable Cells

Alan D. Grinnell and William J. Moody, Jr., *Editors*

Volume 6

Developing and Regenerating Vertebrate Nervous Systems

Penelope W. Coates, Roger R. Markwald, and Alexander D. Kenny, *Editors*

Volume 7

Glutamine, Glutamate, and GABA in the Central Nervous System

Leif Hertz, Elling Kvamme, Edith G. McGeer, and Arne Schousboe, *Editors*

Volume 8

Catecholamines

Earl Usdin, Arvid Carlsson, Annica Dahlström, and Jörgen Engel, *Editors*

Published in three volumes:

Part A: Basic and Peripheral Mechanisms

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

Contributors

G.K. Aghajanian, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, CT 06508 [85]

Luigi F. Agnati, Department of Human Physiology and Endocrinology, University of Modena, I-41100 Modena, Italy [191,441]

Ture Ålander, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]

Harvey J. Altman, Lafayette Clinic, Detroit, MI 48207 [309]

Nils-Erik Andén, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]

Kurt Andersson, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [441]

S. Arbilla, LERS, 58 Rue de la Glaciere, F-75012 Paris, France [135]

T. Archer, Department of Pharmacology, Astra Läkemedel AB, Section AFP, S-151 85 Södertälje, Sweden [285]

G. Aston-Jones, Department of Psychology, SUNY-Binghamton, Binghamton, NY 13901 [159]

David Astrachan, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06508 [245]

J. Axelrod, Section on Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20205 [419]

Michael J. Bannon, MRC Neurochemical Pharmacology Unit, Medical Research Council Center, Hills Road, Cambridge CB2 2GH, UK [25]

M.L. Barbaccia, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy [141]

M.D. Baring, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 [343]

Nino Battistini, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [191]

Fabio Benfenati, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [191,441]

Melvin L. Billingsley, Section on Biochemical Pharmacology, NHLBI, NIH, Bethesda, MD 20205 [37]

G. Blanc, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France [103]

F.E. Bloom, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 [159]

Joël Bockaert, Centre CNRS-INSERM de Pharmacologie-Endocrinologie, F-34100 Montpellier, France [93]

Stefan Borg, Department of Psychiatry, St. Göran's Hospital, S-112 81 Stockholm, Sweden [153]

Benjamin S. Bunney, Departments of Pharmacology and Psychiatry, Yale University School of Medicine, New Haven, CT 06510 [25,313,315,323,369]

Edward B. Bunney, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [25]

Laura Calza, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [441]

Massimo Camurri, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [191,441]

The numbers in brackets are opening page numbers of each author's article.

A complete list of conference participants appears in Catecholamines, Part C.

x / Contributors

Louis A. Chiodo, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510 [25,369]

Randall Commissaris, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06708 [245]

J. Costentin, Laboratoire de Pharmacodynamie et Physiologie, U.E.R. de Médecine et Pharmacie, B.P. 97, F-76800 St. Etienne-du-Rouvray, France [59]

J. Côté, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Quebec G1V 4G2, Canada [409]

Floy L. Crutchfield, Medical Research Service, VA Medical Center and The Medical College of Pennsylvania, Philadelphia, PA 19104 [425]

Gerald Curzon, Institute of Neurology, 33 Johns Mews, London WC1N 2NS, UK [471]

Michael Davis, Department of Psychiatry, Yale University, New Haven, CT 06508 [245]

M. Delandre, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France [59]

Keith T. Demarest, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 [451]

J. Demling, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG [463]

Mary B. Dratman, Veterans Administration Medical Center, Philadelphia, PA 19104 [425]

Alain Enjalbert, Unité de Neuroendocrinologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France [93]

Barry J. Everitt, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [231]

F. Fadda, Institute of Physiology, University of Cagliari, I-09100 Cagliari, Italy [13]

B. Fanni, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy [353]

S.L. Foote, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 [159]

Abraham L. Frankhuyzen, Department of Pharmacology, Free University, Medical Faculty, NL-1081 BT Amsterdam, The Netherlands [47]

William Freed, Department of Health and Human Services, St. Elizabeth's Hospital, Washington, DC 20032 [333]

E. Fuchs, Deutsches Primatenzentrum, BEI MPI Fassberg, D-3400 Göttingen, FRG [463]

Sara Fuchs, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel [137]

Kjell Fuxe, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [191,441]

Dorothy Gallagher, Department of Psychiatry, Yale University, New Haven, CT 06510 [245]

Matthew P. Galloway, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [37]

D.C. German, Department of Physiology, University of Texas Health Science Center, Dallas, TX 75235 [135]

G.L. Gessa, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy [13,353]

Luciana Giardino, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [441]

J. Glowinski, Unité de Neuropharmacologie Biochimie, Collège de France, F-75231 Paris, France [103]

Menek Goldstein, Department of Psychiatry, New York University Medical Center, New York, NY 10016 [231,441]

Janice T. Gordon, Medical Research Service, VA Medical Center and The Medical College of Pennsylvania, Philadelphia, PA 19104 [425]

Maria Grabowska-Andén, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]

Anthony A. Grace, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [25,323]

M. Graf, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG [463]

D.L. Gruol, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 [131,159]

C. Gulat, Laboratoire de Physiologie, Faculté de Pharmacie, F-75005 Paris, France [59]

N.C. Harris, Department of Physiology and Pharmacology, University of Southampton, Southampton SO9 3TU, UK [403]

Thomas G. Heffner, Pharmaceutical Research Division, Warner-Lambert/Parke-Davis, Ann Arbor, MI 48105 [275]

S. Heisler, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 [419]

Barry J. Hoffer, Department of Pharmacology, University of Colorado Medical Center, Denver, CO 80262 [219,333]

Tomas Hökfelt, Karolinska Institute, Department of Histology, S-104 01 Stockholm, Sweden [175,179,191,231]

Robert E. Hruska, Department of Biochemical Pharmacology, State University of New York, Buffalo, NY 14260 [123]

Barry L. Jacobs, Department of Psychology, Princeton University, Princeton, NJ 08544 [393]

Peter W. Kalivas, Department of Pharmacology, Louisiana State University School of Medicine, New Orleans, LA 70112 [199]

H. Keck, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG [463]

John Kehne, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06508 [245]

K. Kiianmaa, Research Laboratories of the Finnish State Alcohol Company (Alko Ltd), SF-00101 Helsinki 10, Finland [145]

M. Knight, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 [343]

Hans Kvande, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden [153]

F. Labrie, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada [409]

A. Laffite, Laboratoire de Physiologie, Faculté de Pharmacie, F-75005 Paris, France [59]

P. Laibe, Laboratoire de Pharmacochimie Moléculaire, Centre de Neurochimie, F-67000 Strasbourg, France [59]

R. Lamberts, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG [463]

T.H. Lanthorn, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 [343]

G. Lefevre, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada [409]

S.F. Leibowitz, The Rockefeller University, New York, NY 10021 [473]

M. Le Moal, Laboratoire de Neurobiologie des Comportements, Université de Bordeaux II, F-33076 Bordeaux cedex, France [293]

T. Lewander, Research Department, Ulleråkers Sjukhus, S-75017 Uppsala, Sweden [169]

Bo Liljenberg, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]

Silvana Lindgren, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]

L. Lucchi, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy [141]

J.M. Lundberg, Department of Pharmacology, Karolinska Institute, S-10401 Stockholm, Sweden [179]

A. Mann, Laboratoire de Pharmacochimie Moléculaire, Centre de Neurochimie, F-67000 Strasbourg, France [59]

T. Mansky, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG [463]

M. Marcou, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy [13]

M.P. Martres, Unité de Neurobiologie, Centre Paul Broca de l'INSERM F-75014 Paris, France [59]

G. Mereu, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy [353]

H. Meunier, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada [409]

E. Mezey, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 [419]

Kenneth E. Moore, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 [451]

E. Mosca, Institute of Physiology, University of Cagliari, I-09100 Cagliari, Italy [13]

Dick Mossberg, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden [153]

Arie H. Mulder, Department of Pharmacology, Free University, Faculty of Medicine, NL-1081 BT Amsterdam, The Netherlands [47]

xii / Contributors

Viktor Mutt, Departments of Histology, Pharmacology, and Biochemistry, Karolinska Institute, S-10401 Stockholm, Sweden [231]

Charles B. Nemeroff, Department of Psychiatry, University of North Carolina, School of Medicine, Chapel Hill, NC 27514 [199]

R.A. North, Neuropharmacology Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139 [207]

Johan Offermeier, Department of Pharmacology, Potchefstroom University, Potchefstroom 2520, South Africa 4 [309]

S.-O. Ögren, Astra Läkemedel AB, Department of Pharmacology, S-151 85 Södertälje, Sweden [285]

Lars Olson, Department of Histology, Karolinska Institute, S-10401 Stockholm, Sweden [219,333]

José M. Palacios, Preclinical Research, Sandoz Ltd., CH-4002 Basel, Switzerland [73]

M. Palkovits, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 [419]

Michael R. Palmer, Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262 [219]

Jorge Pérez-Cruet, Psychiatry Service, Veterans Administration Hospital and the University of Puerto Rico School of Medicine, San Juan 00936, Puerto Rico [271]

Q. Pittman, Division of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada T2N 1N4 [159]

L.A. Pohorecky, Rutgers University, Center of Alcohol Studies, New Brunswick, NJ 08903 [169]

Arthur J. Prange, Jr., Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27514 [199]

P. Protais, U.E.R. de Médecine et Pharmacie, F-76800 St. Etienne-du-Rouvray, France [59]

L. Proulx, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada [409]

D. Eugene Redmond, Jr., Neurobehavior Laboratory, Yale University Medical School, New Haven, CT 06510 [477]

M. Reibaud, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France [103]

T.D. Reisine, Pharmacology Lab, Clinical Science, NIMH, Bethesda, MD 20205 [419]

R.A. Rius, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy [141]

T.W. Robbins, Department of Experimental Psychology and Anatomy, University of Cambridge, Cambridge CB2 3EB, UK [473]

J. Rogers, Department of Neurology, University of Massachusetts Medical Center, Worcester, MA 01605 [159]

S.B. Ross, Department of Pharmacology, Astra Läkemedel AB, S-151 85 Södertälje, Sweden [285]

Z.L. Rossetti, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy [13]

Robert H. Roth, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [3,25,37,43]

Helen E. Savaki, INSERM U 114, Collège de France, F-75005 Paris, France [113]

Anton N.M. Schoffemeer, Department of Pharmacology, Free University, 1081 BT Amsterdam, The Netherlands [47]

Wolfram Schultz, Institute of Physiology, University of Fribourg, CH-1700 Fribourg, Switzerland [401]

Marianne Schultzberg, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [239]

J.-C. Schwartz, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France [59]

Michèle Sebben-Perez, Unité de Neuroendocrinologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France [93]

Lewis S. Seiden, The University of Chicago, Department of Pharmacological and Physiological Sciences, Chicago, IL 60637 [275]

Åke Seiger, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [219]

William J. Shoemaker, The Salk Institute, San Diego, CA 92138 [137]

G.R. Siggins, The Salk Institute, San Diego, CA 92138 [131,159]

- H. Simon**, Laboratoire de Neurobiologie des Comportements, Université de Bordeaux II, F-33076 Bordeaux cedex, France [293]
- P. Sokoloff**, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France [59]
- P.F. Spano**, Department of Pharmacology and Pharmacognosy, University of Milan, 20129 Milano, Italy [141]
- Klaus Starke**, Institute of Pharmacology, Universität Freiburg, D-7800 Freiburg, FRG [5]
- D. Staunton**, 293 Grover Road, St. Louis, MO 63125 [159]
- L. Steardo**, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 [343]
- George F. Steinfels**, Department of Psychology, Princeton University, Princeton, NJ 08544 [393]
- Johannes C. Stoof**, Department of Neurology, Free University, 1081 BT Amsterdam, The Netherlands [47]
- Robert E. Strecker**, Department of Psychology, Princeton University, Princeton, NJ 08544 [393]
- Edward M. Stricker**, Department of Psychology, University of Pittsburgh, Pittsburgh, PA 15260 [259]
- J.M. Studler**, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France [103]
- B. Tabakoff**, Department of Physiology and Biophysics, University of Illinois at Chicago Health Sciences Center, Westside Veterans Administration Medical Center, Chicago, IL 60612 [145]
- J.P. Tassin**, Groupe NB, INSERM U.114, Collège de France, F-75231, Paris cedex 5, France [103]
- Kazuhiko Tatemoto**, Departments of Histology, Pharmacology, and Biochemistry, Karolinska Institute, S-104 01 Stockholm, Sweden [179,231]
- L. Terenius**, Department of Pharmacology, Uppsala University, S-75123 Uppsala, Sweden [179,231]
- Elvar Theodorsson-Norheim**, Department of Pharmacology, Uppsala University, S-75123 Uppsala, Sweden [231]
- Ulla Thornström**, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden [19]
- M. Trabucchi**, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy [141]
- Peter Valverius**, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden [153]
- Dicky Van Heuven-Nolsen**, Rudolf Magnus Institute for Pharmacology, University of Utrecht, NL-3521 GD Utrecht, The Netherlands [213]
- M. Vasse**, Laboratoire de Pharmacodynamie et Physiologie, U.E.R. de Médecine et Pharmacie, B.P. 97, F-76800 St. Etienne-du-Rouvray, France [59]
- Dirk H.G. Versteeg**, R. Magnus Institute, University of Utrecht, Vondellan 6, NL-3521 GD Utrecht, The Netherlands [213]
- M.M. Voigt**, Department of Pharmacology, St. Louis School of Medicine, St. Louis, MO 63104 [359]
- J.R. Walters**, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 [343]
- R.Y. Wang**, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 [359]
- B.L. Waszczak**, National Institute of Neurological and Communicative Disorders and Stroke, NIH, Bethesda, MD 20205 [343]
- Johan Wemer**, Department of Pharmacology, Free University, NL-1081 BT Amsterdam, The Netherlands [47]
- C.G. Wermuth**, Laboratoire de Pharmacochimie Moléculaire, Centre de Neurochimie, F-67000 Strasbourg, France [59]
- F.J. White**, Department of Pharmacology, St. Louis School of Medicine, St. Louis, MO 63104 [359]
- J.T. Williams**, Neuropharmacology Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139 [207]

xiv / Contributors

Marina E. Wolf, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [25]

G.N. Woodruff, Neuroscience Research Center, Merck Sharp & Dohme Ltd., Hoddesdon, Herts EN11 9BU, UK [403]

Suzanne M. Wuerthele, Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262 [333]

W. Wuttke, Department of Reproductive Biology, German Primate Center, D-3400 Göttingen, FRG [463]

Richard Wyatt, Department of Health and Human Services, St. Elizabeth's Hospital, Washington, DC 20032 [333]

Michael J. Zigmond, Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260 [259]

Isabella Zini, Department of Human Physiology, University of Modena, I-41100 Modena, Italy [191]

Contents of Parts A and C

Part A: Basic and Peripheral Mechanisms

A. INTRODUCTION

- 1 Reminiscences / *Hermann Blaschko*
- 2 What About Catecholamines Now? / *Marthe Vogt*
- 3 Protein Phosphorylation in Nervous Tissue / *Eric J. Nestler and Paul Greengard*
- 4 Neurotransmitter Plasticity During the Development of Sympathetic Neurons / *Story C. Landis*
- 5 Transmitter Plasticity in Catecholamine Neurons During Development and Maturity / *I.B. Black, J.E. Adler, M.C. Bohn, G.M. Jonakait, D.M. Katz, J.A. Kessler, and K.A. Markey*

B. STORAGE, RELEASE, AND UPTAKE

- 6 Early Theories of Chemical Transmission / *J.S. Gillespie*
- 7 Large and Small Noradrenergic Vesicles—Origin, Contents, and Functional Significance / *Gabriel Fried, Hugo Lagercrantz, Richard Klein, and Åsa Thureson-Klein*
- 8 Chemical Nature of Vesicular NE Storage and Release—Different Theories / *Börje Uvnäs*
- 9 Is the Vesicle the Unit of Transmission at the Sympathetic Neuroeffector Junction? Electrophysiological Evidence / *A.G.H. Blakeley, A. Mathie, and S.A. Petersen*
- 10 The Roles of Large and Small Noradrenergic Vesicles in Exocytosis / *Åsa Thureson-Klein*
- 11 Do Storage Vesicles of Peripheral Sympathetic Nerves Have More Than One Life Cycle? / *Arun R. Wakade and Taruna D. Wakade*
- 12 Studies on the Economy of Amine Storage Granules in the Nerve Terminals of Adrenergic Neurons / *Jan Häggendal*
- 13 Kinetics of Norepinephrine (NE) and Dopamine β -Hydroxylase (DBH) Overflow From Isolated Hearts / *E. Muscholl*
- 14 Catecholamines in Perinatal Medicine: Introduction / *Colin T. Jones and Hugo Lagercrantz*
- 15 Catecholamine Surge at Birth in the Human Infant / *Hugo Lagercrantz*
- 16 The Effects of Adrenal Medullary Activity on the Sensitivity to Catecholamine Stimulation of the Sympathetic System in Fetal Sheep / *Colin T. Jones, Margaret M. Roebuck, and David W. Walker*
- 17 Role of Adrenomedullary Catecholamine Release in Survival During Neonatal Hypoxia / *Theodore A. Slotkin and Frederic J. Seidler*
- 18 The Importance of the Pattern of Activity in Sympathetic Nerves / *A.V. Edwards, P.M.M. Bircham, B.N. O'Connor, M.A. Ghatei, G.P. McGregor, T.E. Adrian, and S.R. Bloom*
- 19 Catecholamines in Perinatal Medicine: Conclusions / *Colin T. Jones and Hugo Lagercrantz*
- 20 Development of Catecholamine Mechanisms: Summary / *C. Kellogg and G. Jonsson*
- 21 Uptake and Storage: Summary / *Charles O. Rutledge*

C. RELEASE AND METABOLISM

- 22 Adrenal Medulla: Regulation of Biosynthesis and Secretion of Catecholamines and Enkephalins / *E. Costa, A. Guidotti, I. Hanbauer, H. Kageyama, Y. Kataoka, P. Panula, T.T. Quach, and J.P. Schwartz*

- 23 Plasma Catecholamines as Markers for Sympathoadrenal Activity in Man: Workshop Summary / *Börje Uvnäs and Paul Hjemdahl*
- 24 Release and Metabolism of Catecholamines: Summary / *D.M. Paton and B.B. Fredholm*
- 25 Catecholamine Release and Metabolism: Summary / *Gaetano Di Chiara and Peter Waldmeier*
- 26 Catecholamine Degrading Enzymes: Summary / *Albert Zeller and Lars Oreland*

D. CATECHOLAMINE SYNTHESIS

- 27 Studies of the Mechanism of Activation of Tyrosine Hydroxylase In Situ in PC 12 Cells / *N. Weiner, N. Yanagihara, A.W. Tank, L. Baizer, and T.A. Langan*
- 28 Molecular Aspects: Regulation of Tyrosine 3-Monooxygenase Activity / *Hitoshi Fujisawa, Sachiko Okuno, and Takashi Yamauchi*
- 29 Studies on Phosphorylation of Tyrosine Hydroxylase / *Menek Goldstein, Kwan Y. Lee, Esther L. Sabban, John Seeley, and Lloyd Greene*
- 30 Stimulation-Dependent Regulation of Catecholamine Biosynthesis in Purified Adrenal Chromaffin Cells: Phosphorylation and Activation of Tyrosine Hydroxylase / *Jack C. Waymire, John W. Haycock, and Robert J. George*
- 31 Similar Gene Coding Regions for Catecholamine Biosynthetic Enzymes: Possible Existence of Ancestral Precursor Gene / *Tong H. Joh, E. Edward Baetge, M. Elizabeth Ross, and Donald J. Reis*
- 32 Molecular Biology of Tyrosine Hydroxylase / *N. Faucon Biguet, C. Boni, M. Buda, B. Grima, J.F. Julien, A. Lamouroux, and J. Mallet*
- 33 Catecholamine-Synthesizing Enzymes: Summary / *Toshiharu Nagatsu and Ikuko Nagatsu*

E. RECEPTORS

- 34 Multiple Dopamine Receptors: Relevance of In Vitro Binding Data for Subclassification of Binding Sites / *J.E. Leysen*
- 35 Studies on Solubilization and Characterization of Rat Striatal Dopamine Receptors / *Menek Goldstein and Jow Y. Lew*
- 36 Isolation and Characterization of Dopamine Receptor Protein / *P.M. Laduron and W. Wouters*
- 37 Brain D₂-Dopamine Receptors: Isolation and Characterization / *Philip G. Strange, W. Mark Abbott, and Mark Wheatley*
- 38 Interactions of Agonists and Antagonists With β -Adrenergic Receptors on Intact S49 Lymphoma Cells / *P.B. Molinoff, D. Hoyer, and E.E. Reynolds*
- 39 Agonist-Mediated Conformational Modification of β -Adrenergic Receptors / *G. Vauquelin, Y. Severne, S. Bottari, and C. Andre*
- 40 Specific Lipid Requirements in Reconstitution of the β -Adrenergic Receptor Function / *M. Schramm, J. Kirilovsky, and Y. Citri*
- 41 Molecular Characterization of Adrenergic Receptors by Affinity Chromatography and Photoaffinity Labeling / *Marc G. Caron, John W. Regan, Kenneth E.J. Dickenson, L.M. Fredrik Leeb-Lundberg, Jeffrey L. Benovic, Jarl E.S. Wikberg, Sarah L. Heald, Robert M. DeMarinis, John F. DeBernardis, and Robert J. Lefkowitz*
- 42 The Structure of Neurotransmitter Receptors (Adrenergic, Dopaminergic, and Muscarinic Cholinergic) / *J. Craig Venter, Claire M. Fraser, Leslie Lilly, Philip Seeman, Barbara Eddy, and Jayne Schaber*
- 43 Characterization of Adrenoceptors in the Brain and the Periphery: Summary / *David S. Janowsky*

F. CARDIOVASCULAR REGULATION

- 44 Cardiovascular Regulation and Catecholamines: Introduction / *Walter Lovenberg*
- 45 Sympathetic Neurotransmitter Activity and Congestive Heart Failure / *Michael J. Sole*
- 46 Noradrenergic Transmission in Blood Vessels: Influence of Hypertension and Dietary Sodium / *Thomas C. Westfall, Michael J. Meldrum, Laurice Badino, and Chun-Sheng Xue*
- 47 Central Cholinergic-Noradrenergic Interactions and Blood Pressure Control / *David S. Janowsky, Samuel Craig Risch, Michael Ziegler, Brian Kennedy, Lewis L. Judd, and Leighton Y. Huey*

- 48 Role of Peripheral Dopamine in Essential Hypertension / *Otto Kuchel and Nguyen T. Buu*
- 49 Catecholamines and the Cardiovascular System: Recent Advances in Biochemical Evaluation of Adrenergic Activity / *Irwin J. Kopin*
- 50 Catecholamines in Ischemia: Summary / *U. Trendelenburg and O. Almgren*
- 51 Cardiovascular and Respiratory Mechanisms: Summary / *Robert Stitzel and Bevyen Jarrott*
- 52 Catecholamines and Catecholamine Receptors in Stress and Hypertension: Summary / *Donald J. Reis and John P. Chalmers*
- 53 Plasma Catecholamine Measurements in Stress and Hypertension: Summary / *R. Kvetňanský and H. Grobecker*
- 54 Characteristics of Spontaneous Efferent Splanchnic Discharge in Neonatal Swine / *P.M. Gootman, H.L. Cohen, S.M. DiRusso, A.P. Rudell, and L.P. Eberle*

Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

A. CATECHOLAMINES IN PSYCHIATRIC DISORDERS

- 1 A Reevaluation of the Catecholamine Hypothesis in Affective Disorders / *William E. Bunney, Jr. and Blynn L. Garland*
- 2 Catecholamines and Schizophrenia: An Assessment of the Evidence / *T.J. Crow, A.J. Cross, J.A. Johnson, E.C. Johnstone, M.H. Joseph, F. Owen, D.G.C. Owens, and M. Poulter*
- 3 Psychopharmacology and Schizophrenia: Summary / *M. Ackenheil and S. Algeri*
- 4 Psychopharmacology and Schizophrenia: Summary / *B. Angrist and C. Tamminga*
- 5 Catecholamines in Affective Disorders: Summary / *Keith Wood and Ole J. Rafaelsen*

B. MOTOR MALFUNCTIONS

- 6 Catecholamine Mechanisms and Motor Malfunction: Introduction / *Thomas N. Chase*
- 7 Neuropeptides in Parkinson's Disease / *F. Javoy-Agid, H. Taquet, F. Cesselin, J. Epelbaum, D. Grouselle, A. Mauborgne, J.M. Studier, and Y. Agid*
- 8 Neurochemistry of Monoaminergic Neurons in Parkinson's Disease / *B. Scatton, F. Javoy-Agid, J.C. Montfort, and Y. Agid*
- 9 Progabide in Decompensated Parkinson's Disease: Implications of Dopaminergic-GABAergic Interactions for Levodopa-Induced Fluctuations / *Kenneth J. Bergmann, Joao C.P. Limongi, Young-Hee Lowe, Marina R. Mendoza, and Melvin D. Yahr*
- 10 Abnormal Involuntary Movements in Schizophrenia: Neurochemical Correlates and Relation to the Disease Process / *T.J. Crow, S.R. Bloom, A.J. Cross, I.N. Ferrier, E.C. Johnstone, F. Owen, D.G.C. Owens, and G.W. Roberts*
- 11 Tardive Dyskinesia: GABA Agonist Treatment / *C.A. Tamminga, G.K. Thaker, and S.T. Goldberg*
- 12 Primary (Initial) and Secondary (Tardive) Dyskinesia: Effect of Fluperlapine, a New Atypical Neuroleptic Drug / *J. Gerlach, S. Korsgaard, and U. Noring*
- 13 Studies in Experimental Tardive Dyskinesia / *Lars M. Gunne and Jan-Erik Häggström*
- 14 Monkey Models of Tardive Dyskinesia / *Edward F. Domino and Beverly Kovacic*
- 15 Comparison of the Effects on Striatal Dopamine Receptor Function of Chronic Administration of Haloperidol, Clozapine, or Sulpiride to Rats for Up to 12 Months / *N.M.J. Rupniak, S. Mann, M.D. Hall, P. Jenner, and C.D. Marsden*
- 16 Animal Models for Neuroleptic-Induced Neurological Dysfunction / *A.V. Christensen, J. Arnt, and O. Svendsen*
- 17 Catecholamine Mechanisms and Motor Malfunction: Summary / *Yves Agid and Peter Riederer*

C. CEREBROSPINAL FLUID CONCENTRATION OF AMINES AND METABOLITES

- 18 Cerebrospinal Fluid Concentrations of Amines and Metabolites: Clinical and Methodological Perspectives / *Robert M. Post*

xviii / Contents of Part C

- 19 Cerebrospinal Fluid Norepinephrine Metabolites in Depressed Patients: New Methodologies / *D.C. Jimerson, D.R. Rubinow, J.C. Ballenger, R.M. Post, and I.J. Kopin*
- 20 Psychiatric Morbidity Within the Family and Steady-State Levels of Cerebrospinal Fluid Monoamine Metabolites / *F.-A. Wiesel, L. Bjerksten, J. Herlofsson, C. Härnryd, H. Nybäck, G. Oxenstierna, and G. Sedvall*
- 21 Brain and Cerebrospinal Fluid-Epinephrine in Isocarboxazide- and Zimeldine-Treated Rats / *Annette Gjerris, David I. Barry, Niels Juel Christensen, and Ole J. Rafaelsen*
- 22 Systems Theory as a Tool for Integrating Functional Interactions Among Biogenic Amines / *Kym F. Faull, Roy J. King, Philip A. Berger, and Jack D. Barchas*
- 23 Cerebrospinal Fluid Amine Metabolites and Neuroendocrine Changes in Psychoses and Suicide / *C.M. Banki, M. Arató, Z. Papp, and M. Kurcz*
- 24 Cerebroventricular Volume, Cerebrospinal Fluid Monoamine Metabolites, and Intellectual Performance in Schizophrenic Patients / *H. Nybäck, B.-M. Berggren, H. Nyman, G. Sedvall, and F.-A. Wiesel*
- 25 Cortical Atrophy and Enlarged Ventricles Associated With Low Levels of Cerebrospinal Fluid Monoamine Metabolites and Dopamine- β -Hydroxylase Activity in Schizophrenia / *Daniel P. Van Kammen, Lee S. Mann, David E. Sternberg, Mika Scheinin, Philip T. Ninan, Welmoet B. Van Kammen, and Markku Linnola*
- 26 Cerebrospinal Fluid Cyclic Nucleotides in Schizophrenia / *Robert H. Belmaker, Daniel Stein, Daniel Weinberger, Steve G. Potkin, and Richard J. Wyatt*

D. PHARMACOLOGY

- 27 3-(3-Hydroxyphenyl)-N-n-propylpiperidine (3-PPP)—A Novel Tool for the Characterization of Dopamine Receptors / *Arvid Carlsson*
- 28 Workshop on the Chemistry and Biology of Ring-Fluorinated Catecholamines: Summary / *Cyrus R. Creveling*

E. REGENERATION

- 29 Intrastriatal Chromaffin Grafts in Experimental and Clinical Parkinsonism: First Impressions / *L. Olson, E.-O. Backlund, G. Sedvall, M. Herrera-Marschitz, U. Ungerstedt, I. Strömberg, B. Hoffer, and Å. Seiger*
- 30 Implantation of Suspensions of Dissociated Dopamine Neurons in the Rat Brain / *Anders Björklund, Stephen B. Dunnett, Fred H. Gage, and Ulf Stenevi*
- 31 Transplantation of Peptidergic and Aminergic Neurons / *John R. Sladek, Jr., Don M. Gash, and Timothy J. Collier*
- 32 A Role for Exogenous Gangliosides in the Functional Recovery of Adult Lesioned Nervous System / *G. Toffano, G. Savoini, C. Aldinio, M. Valenti, G. Lombardi, F. Moroni, L.F. Agnati, and K. Fuxe*
- 33 Anatomy, Plasticity, and Regeneration: Summary / *Fred H. Gage*
- 34 Concluding Remarks: Shaking the Kaleidoscope / *M. Sandler*

Preface

The proceedings of the Fifth International Catecholamine Symposium (5 CA), which was held in Göteborg, Sweden (June 1983), are being published as a set of three volumes, which are also available as individual, independent volumes: A. Basic and Peripheral Mechanisms; B. Neuropharmacology and Central Nervous System—Theoretical Aspects; C. Neuropharmacology and Central Nervous System—Therapeutic Aspects. There are certain redundancies: complete Table of Contents, Index, Abbreviations are included in each volume. Although each volume is an entity on its own, owners of one volume will, hopefully, see intriguing entries in the Table of Contents or the Subject Index which will impel them to buy the other volumes. The list of committee members appears in Part A only, and the list of conference participants in Part C only.

Earl Usdin

P.S.*

During the printing of this volume, we were reached by the message that our colleague and dear friend, Earl Usdin, died on May 26, 1984. He had been ill for some time, and his death was not unexpected. Nevertheless, we are struck by sorrow and a feeling of deep loss. The scientific community has lost a highly talented and dedicated worker with an extraordinary command of the English language. Earl Usdin was, with his warm-hearted, generous personality and unique talent for organization, the catalyst of so many international scientific meetings in the field of neuropsychopharmacology, including the CA meetings. He mastered the editing of an impressive number of volumes, more than sixty, thus collecting essential new knowledge in comprehensive units.

Earl Usdin's activities were characterized by dedication, excellence, and a deep sense of humor. He guided the organization of 5 CA in a way which created feelings of friendship, professional admiration, and, now, a sense of loss in our minds. We regret that he was not given the opportunity to pursue his important work as organizer of scientific meetings and editor of books, now that his new position at Irvine had evidently created excellent conditions for this sort of work which was so close to his heart and which he mastered so well. We likewise regret that he was not given the satisfaction of seeing the present three volumes of the 5 CA proceedings, to which he had devoted so much effort.

Earl Usdin has left the catecholamine field, but his spirit will remain with us. All his friends in neuropsychopharmacology will cherish his memory.

**Arvid Carlsson
Annica Dahlström
Jörgen Engel**

*We are grateful to Alan R. Liss, Inc., for stopping the presses to enable the inclusion of this post script.

Abbreviations

- AA = ascorbic acid *or* Alko alcohol (rats)
 AADC = (aromatic) amino acid decarboxylase
 AC = adenylate cyclase
 ACh = acetylcholine
 AChE = acetylcholinesterase
 ACSF = artificial CSF
 ACTH = adrenocorticotrop(h)in
 ADDPS = acute dyskinetic, dystonic, parkinsonism syndrome
 ADH = antidiuretic hormone
 ADP = adenosine diphosphate
 (6,7)ADTN = 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene
 AHP = after-hyperpolarization
 AIMS = Abnormal Involuntary Movement Scale
 Alko = Finnish State Alcohol Monopoly
 AMI = amitriptyline
 AMP = adenosine monophosphate
 AMPH = amphetamine
 AMPT = α -methyl-*p*-tyrosine
 ANA = Alko nonalcohol (rats)
 ANOVA = analysis of variance
 ANT = alcohol nontolerant (strain)
 4-AP = 4-aminopyridine
 APDQ = 4-amino-6,7-dimethoxy-2[4'-(5''(3'''-iodo-4'''-azidophenyl)pentanoyl]-1'-piperazinyl)quinazoline
 APO = apomorphine
 APP = avian pancreatic polypeptide
 App(NH)p = adenosylimidophosphate
 AT = angiotensin *or* alcohol tolerant (strain)
 ATP = adenosine triphosphate
 ATPase = adenosine triphosphatase
 AVP = (arginine)vasopressin
 AVP-A = [Asu^{1,6}Arg⁸]vasopressin
 BAC = blood alcohol concentration(s)
 BAT = brown adipose tissue
 BBB = blood-brain barrier
 BH₄ = tetrahydrobiopterin
 BiP = bipolar
 BLI = bombesin-like immunoreactivity
 BMB = bombesin
 BP = blood pressure
 BPI = bipolar I
 BPII = bipolar II
 BPP = bovine pancreatic polypeptide
 BPRS = Brief Psychiatric Rating Scale
 BRO = bromocriptine
 BSA = bovine serum albumin
 BZD = benzodiazepine(s)
 CA = catecholamine(s)
 Ca = calcium (ion)
 CaM = calmodulin
 cAMP = cyclic AMP
 CAR = conditioned avoidance response
 CAT = computer axial tomography
 CBZ = carbamazepine
 CCK = cholecystokinin
 Cd = cadmium (ions)
 cDNA = complementary DNA
 cGMP = cyclic GMP
 ChAT = choline acetyltransferase
 ChE = cholinesterase
 CHF = congestive heart failure
 CLG = cyclo(leucine-glycine)
 CM = conditioned medium (by heart cells)
 CNS = central nervous system
 COMT = catecholamine O-methyltransferase
 ConA = concanavallin A
 CPRS = Comprehensive Psychopathological Rating Scale
 CPZ = chlorpromazine